Laboratorio Reig Jofre, S.A. Share Price

Equities

RJF

ES0165359029

Pharmaceuticals

Market Closed - BME 16:35:26 26/04/2024 BST 5-day change 1st Jan Change
2.58 EUR +2.38% Intraday chart for Laboratorio Reig Jofre, S.A. +1.98% +14.67%

Financials

Sales 2022 274M 293M 23.48B Sales 2023 318M 340M 27.22B Capitalization 177M 190M 15.18B
Net income 2022 8M 8.55M 685M Net income 2023 9M 9.62M 771M EV / Sales 2022 0.82 x
Net Debt 2022 54.76M 58.55M 4.69B Net Debt 2023 47.92M 51.23M 4.1B EV / Sales 2023 0.71 x
P/E ratio 2022
21.9 x
P/E ratio 2023
18.8 x
Employees 1,331
Yield 2022
1.83%
Yield 2023
-
Free-Float 19.99%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Spain’s Reig Jofre Names New CFO MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Laboratorio Reig Jofre, S.A., Q4 2022 Earnings Call, Mar 07, 2023
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Why Europe's drug shortages may get worse RE
Reig Jofre JV Inks Deal with Indian Pharmaceutical to Commercialize Biosimilar Medicine MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Laboratorio Reig Jofre, S.A.(BME:RJF) dropped from S&P Global BMI Index CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Laboratorio Reig Jofre, S.A.’s Equity Buyback announced on July 18, 2019 has Expired. The company has repurchased 74,107 shares, representing 0.1% for €0.26 million. CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news
1 day+2.38%
1 week+1.98%
Current month+3.61%
1 month+3.20%
3 months+8.40%
6 months+17.27%
Current year+14.67%
More quotes
1 week
2.46
Extreme 2.46
2.60
1 month
2.46
Extreme 2.46
2.78
Current year
2.21
Extreme 2.21
2.78
1 year
2.15
Extreme 2.15
2.88
3 years
2.02
Extreme 2.02
5.79
5 years
1.87
Extreme 1.87
6.40
10 years
1.87
Extreme 1.87
9.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 31/12/05
Chief Tech/Sci/R&D Officer - 31/12/02
Chief Operating Officer 52 31/12/02
Members of the board TitleAgeSince
Chief Executive Officer 56 31/12/05
Director/Board Member - 30/12/14
Director/Board Member - 30/12/14
More insiders
Date Price Change Volume
26/04/24 2.58 +2.38% 8,932
25/04/24 2.52 0.00% 4,940
24/04/24 2.52 -0.40% 2,788
23/04/24 2.53 +0.40% 3,071
22/04/24 2.52 -0.40% 20,523

Delayed Quote BME, April 26, 2024 at 04:35 pm

More quotes
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
More about the company

Annual profits - Rate of surprise